全球病毒清除市场规模（按方法、应用程式、最终用户、地区、范围和预测）

病毒清除市场规模及预测

预计2024年病毒清除市值为6.2837亿美元，预计2024年至2031年期间复合年增长率为12.21%，到2031年将达到14.5527亿美元。

病毒清除的全球市场推动因素

病毒清除市场的市场推动因素可能会受到多种因素的影响。

对生物製药的需求不断增加：

生物製药的需求也同时增加，需要实施严格的病毒清除程序以确保产品安全。基因疗法、疫苗和单株抗体等生物製药经常含有生物物质，因此清除病毒至关重要，以防止病毒污染物的传播。

严格的监理义务：

欧洲药品管理局（EMA）、美国食品药物管理局（FDA）等监管机构对生物製药生产中的病毒清除制定了严格的标准。遵守这些规定是我们引入尖端病毒清除技术和服务的动力。

病毒感染增加：

病毒感染的增加，包括肝炎、爱滋病毒/爱滋病以及伊波拉和寨卡等新出现的病毒，凸显了实施有效的病毒清除策略的重要性。在这样的发展背景下，必须不断改进病毒清除技术，以对抗不断变化的病毒威胁。

生物製程开发：

生物加工技术的进步，包括净化、细胞培养和分析测定，有助于提高病毒清除能力。这些发展使生物製药公司能够提高其病毒清除程序的有效性和可靠性。

生物製造业的成长：

病毒清除解决方案的需求受到生物製造业扩张的推动，这受到新型生物製剂和生物相似药发展的推动。与生物製药市场的预期成长轨迹类似，病毒清除市场也预计将持续扩大。

增加病毒清除服务的外包：

生物製药行业越来越多地将病毒清除测试和验证的责任委託给专门的合约研究组织 (CRO) 和合约製造组织 (CMO)。对病毒清除活动中的专业知识、基础设施和成本效益的需求是推动这种外包趋势的因素。

新兴的病毒清除技术：

新型病毒清除技术的出现是正在进行的研究和开发的主题。这些技术旨在提高功效、速度和成本效益。色谱技术、病毒灭活技术和下一代过滤方法等技术创新正在推动市场扩张。

製药製造业的全球化：

製药製造的全球化是不同地区广泛实施标准化病毒清除程序的关键推动因素。在多个国家运营的组织努力遵守全球监管规范，因此世界各地对病毒清除解决方案产生了浓厚的兴趣。

限制全球病毒清除市场的因素

有几个因素可能会对病毒清除市场造成限制和课题。

严格的监理要求：

严格的监管要求：监管机构有严格的指导方针和标准，以确保生物製剂的病毒清除。这可能会促使更长的开发和审批流程以及增加成本。

病毒清除程式成本高：

病毒清除程序通常需要使用复杂的技术和设备，其购买和维护成本很高。由于成本过高，较小的组织和企业可能不愿意进入这个市场。

病毒清除程式的复杂性：

与病毒清除相关的课题病毒清除程序可能很困难并且需要专业知识。在尝试设计和实施有效的病毒清除策略时，组织可能会遇到困难。

产品污染风险：

儘管实施了严格的病毒清除协议，但产品污染仍然存在可能性，从而促使昂贵的产品召回和声誉损害。

可扩充性限制：

某些病毒清除方法可能难以满足大规模生产的要求，尤其是对于高产量生物製药产品而言。

新的病毒威胁：

病毒根除策略面临病毒不断演化带来的课题。新出现或新型病毒的出现可能需要开发新的控制方法，从而增加市场的复杂性和不可预测性。

与替代技术的衝突：

替代技术相对于传统病毒清除方法的脆弱性意味着它们可能面临旨在灭活或去除病毒的过滤和热处理等技术的竞争。

道德与安全考量：

使用某些含有潜在危险化合物或动物源产品的病毒清除方法可能会引发伦理问题。

目录

第 1 章 全球病毒清除市场简介

市场概况
• 研究范围
• 先决条件

第 2 章执行摘要

第 3 章：经过验证的市场研究方法

• 资料探勘
• 验证
• 主要来源
• 资料来源列表

第 4 章 全球病毒清除市场展望

• 概述
• 市场动态
  • 驱动程式
  • 阻碍因素
  • 机会
• 波特五力模型
• 价值链分析

第 5 章全球病毒清除市场（依方法论）

• 概述
• 病毒清除
• 病毒灭活

第6章 全球病毒清除市场（按应用）

• 概述
• 重组蛋白
• 血液和血液製品
• 疫苗
• 其他

第7章 全球病毒清除市场（按最终用户）

• 概述
• 製药和生技公司
• 合约研究组织
• 学术研究机构
• 其他

第8章 全球病毒清除市场（按地区）

• 概述
• 北美洲
  • 美国
  • 加拿大
  • 墨西哥
• 欧洲
  • 德国
  • 英国
  • 法国
  • 其他欧洲国家
  亚太地区
  • 中国
  • 日本
  • 印度
  • 其他亚太地区
• 世界其他地区
  • 拉丁美洲
  • 中东和非洲

第 9 章全球病毒清除市场的竞争格局

• 概述
• 各公司的市场排名
• 主要发展策略

第10章 公司简介

• Charles River Laboratories International
• Merck KGaA
• Wuxi Biologics（Cayman）（Subsidiary of Wuxi Apptec）
• Texcell
• Kedrion
• Bsl Bioservice
• Vironova Biosafety
• Clean Cells
• Virusure GmbH

第11章 附录

• 关联调查

Viral Clearance Market Size And Forecast

Viral Clearance Market size was valued at USD 628.37 Million in 2024 and is projected to reach USD 1455.27 Million by 2031 , growing at a CAGR of 12.21% during the forecasted period 2024 to 2031.

Global Viral Clearance Market Drivers

The market drivers for the Viral Clearance Market can be influenced by various factors. These may include: Increasing Demand for Biopharmaceuticals:

The demand for biopharmaceuticals is experiencing a concurrent increase, necessitating the implementation of rigorous viral clearance procedures to guarantee the safety of the products. Biopharmaceuticals, such as gene therapies, vaccines, and monoclonal antibodies, frequently incorporate biological substances; therefore, viral clearance is of the utmost importance in order to avert the spread of viral contaminants.

Strict regulatory obligations:

Regulatory agencies, including the European Medicines Agency (EMA) in Europe and the Food and Drug Administration (FDA) in the United States, impose rigorous criteria for viral clearance in the manufacturing of biopharmaceuticals. Compliance with these regulations motivates the implementation of cutting-edge technologies and services for viral clearance.

An increasing prevalence of viral infections:

The growing incidence of viral infections, including hepatitis, HIV/AIDS, and emergent viruses such as Ebola and Zika, highlights the criticality of implementing efficient viral clearance strategies. On account of this development, ongoing advancements in viral clearance technologies are required to combat the ever-changing viral threats.

Developments in Bioprocessing Methods:

Bioprocessing technological advancements, such as methods for purification, cell culture, and analytical assays, contribute to enhanced viral clearance capabilities. These developments empower biopharmaceutical firms to improve the effectiveness and dependability of viral clearance procedures.

Growing Biomanufacturing Sector:

Growing The demand for viral clearance solutions is fueled by the expanding biomanufacturing sector, which is propelled by the development of novel biologics and biosimilars. Consistent with the anticipated growth trajectory of the biopharmaceutical market, the viral clearance market is anticipated to experience ongoing expansion.

Increasing Outsourcing of Viral Clearance Services:

A growing trend in the biopharmaceutical industry is the delegation of viral clearance testing and validation responsibilities to specialized contract research organizations (CROs) and contract manufacturing organizations (CMOs). In viral eradication activities, the demand for specialized knowledge, infrastructure, and cost-efficiency motivates this outsourcing trend.

Emergence of Novel Viral Clearance Technologies:

The emergence of novel viral clearance technologies is the subject of ongoing research and development. These technologies aim to provide enhanced effectiveness, velocity, and cost-effectiveness. Market expansion is aided by innovations including chromatography techniques, viral inactivation technologies, and filtration methods of the next generation.

Globalization of Pharmaceutical Manufacturing:

The globalization of pharmaceutical manufacturing is a significant factor in the widespread implementation of standardized viral clearance procedures in various geographic areas. Organizations that have operations in numerous nations strive to conform to global regulatory norms, which has generated significant interest in viral clearance solutions worldwide.

Global Viral Clearance Market Restraints

Several factors can act as restraints or challenges for the Viral Clearance Market. These may include:

Stringent Regulatory Requirements:

Regulatory bodies enforce rigorous guidelines and criteria to ensure the viral clearance of biological products. This can result in extended development and approval processes, as well as increased costs.

High Cost of Viral Clearance Procedures:

Viral clearance procedures frequently necessitate the use of sophisticated technology and apparatus, the acquisition and upkeep of which can be quite costly. Smaller organizations or corporations may be dissuaded from entering the market by the exorbitant expense.

Complexity of Viral Clearance Procedures:

Difficulties Associated with Viral Clearance Procedures for viral clearance can be difficult and demand specialized knowledge. Organizations might encounter difficulties when attempting to devise and execute efficient viral clearance strategies.

Risk of Product Contamination:

Notwithstanding the implementation of stringent viral clearance protocols, the potential for product contamination remains, resulting in expensive product recalls and reputational harm.

Scalability Constraints:

Certain viral clearance methods might present challenges in accommodating the requirements of large-scale production, especially in the case of biopharmaceuticals with substantial volume of output.

Emerging Viral Threats:

Viral eradication strategies face a challenge posed by the perpetual evolution of viruses. Emerging viruses or new viral variants may necessitate the development of novel clearance methods, thereby increasing market complexity and unpredictability.

Competition from Alternative Technologies:

Alternative Technologies Vulnerabilities to Traditional Viral Elimination Methods may face competition from technologies such as filtration or thermal treatment that aim to inactivate or eliminate viruses.

Ethical and Safety Considerations:

The utilization of specific viral clearance methods that incorporate potentially hazardous compounds or animal-derived products may give rise to ethical concerns.

Global Viral Clearance Market: Segmentation Analysis

The Global Viral Clearance Market is Segmented on the basis of Method, Application, End-User, And Geography.

Viral Clearance Market, By Method

• Viral Removal
• Viral Inactivation

Based on the Method, The market is bifurcated into Viral Removal and Viral Inactivation. The Viral Removal segment is expected to hold the largest market share. The factors can be attributed to the high acceptance of this method, the growth of R&D activities by biopharmaceutical companies, and the accuracy, speed, & flexibility provided by the method in life sciences research.

Viral Clearance Market, By Application

• Recombinant Proteins
• Blood and Blood Products
• Vaccines
• Others

Based on the Application, The market is bifurcated into Recombinant Proteins, Blood and Blood Products, Vaccines, and Others. The other segment is predicted to hold the most significant CAGR in the forecasted period due to the growing public & private funding for stem cell research, the use of tissue-based therapies to treat various diseases, and the rising use of cellular therapies in the treatment of various disorders.

Viral Clearance Market, By End-User

• Pharmaceutical & Biotechnology Companies
• Contract Research Organizations
• Academic Research Institutes
• Others

Based on End-User, The market is bifurcated into Pharmaceutical & Biotechnology Companies, Contract Research Organizations, Academic Research Institutes, and Others. The Contract Research Organizations segment is anticipated to hold the largest market share. The factors can be credited for the increasing outsourcing of Drug Discovery Services to CROs by pharmaceutical companies, academic institutes, small biotechnology companies, & start-ups and the ability of CROs to invest in extensive drug discovery infrastructure.

Viral Clearance Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the World

Based on Regional Analysis, The Global Viral Clearance Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. The largest share in the market will be dominated by North America owing to growth in the pharmaceuticals industry, rising number of drug approvals, and the presence of national institutes supporting biotechnology and life science research in this region.

Key Players

• Charles River Laboratories International
• Merck KGaA
• Wuxi Biologics (Cayman) (Subsidiary of Wuxi Apptec)
• Texcell
• Kedrion
• Bsl Bioservice
• Vironova Biosafety
• Clean Cells Virusure GmbH

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL VIRAL CLEARANCE MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL VIRAL CLEARANCE MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL VIRAL CLEARANCE MARKET, BY METHOD

• 5.1 Overview
• 5.2 Viral Removal
• 5.3 Viral Inactivation

6 GLOBAL VIRAL CLEARANCE MARKET, BY APPLICATION

• 6.1 Overview
• 6.2 Recombinant Proteins
• 6.3 Blood and Blood Products
• 6.4 Vaccines
• 6.5 Others

7 GLOBAL VIRAL CLEARANCE MARKET, BY END-USER

• 7.1 Overview
• 7.2 Pharmaceutical & Biotechnology Companies
• 7.3 Contract Research Organizations
• 7.4 Academic Research Institutes
• 7.5 Others

8 GLOBAL VIRAL CLEARANCE MARKET, BY GEOGRAPHY

• 8.1 Overview
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 U.K.
  • 8.3.3 France
  • 8.3.4 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Rest of Asia Pacific
• 8.5 Rest of the World
  • 8.5.1 Latin America
  • 8.5.2 Middle East and Africa

9 GLOBAL VIRAL CLEARANCE MARKET COMPETITIVE LANDSCAPE

• 9.1 Overview
• 9.2 Company Market Ranking
• 9.3 Key Development Strategies

10 COMPANY PROFILES

• 10.1 Charles River Laboratories International
  • 10.1.1 Overview
  • 10.1.2 Financial Performance
  • 10.1.3 Product Outlook
  • 10.1.4 Key Developments
• 10.2 Merck KGaA
  • 10.2.1 Overview
  • 10.2.2 Financial Performance
  • 10.2.3 Product Outlook
  • 10.2.4 Key Developments
• 10.3 Wuxi Biologics (Cayman) (Subsidiary of Wuxi Apptec)
  • 10.3.1 Overview
  • 10.3.2 Financial Performance
  • 10.3.3 Product Outlook
  • 10.3.4 Key Developments
• 10.4 Texcell
  • 10.4.1 Overview
  • 10.4.2 Financial Performance
  • 10.4.3 Product Outlook
  • 10.4.4 Key Developments
• 10.5 Kedrion
  • 10.5.1 Overview
  • 10.5.2 Financial Performance
  • 10.5.3 Product Outlook
  • 10.5.4 Key Developments
• 10.6 Bsl Bioservice
  • 10.6.1 Overview
  • 10.6.2 Financial Performance
  • 10.6.3 Product Outlook
  • 10.6.4 Key Developments
• 10.7 Vironova Biosafety
  • 10.7.1 Overview
  • 10.7.2 Financial Performance
  • 10.7.3 Product Outlook
  • 10.7.4 Key Developments
• 10.8 Clean Cells
  • 10.8.1 Overview
  • 10.8.2 Financial Performance
  • 10.8.3 Product Outlook
  • 10.8.4 Key Developments
• 10.9 Virusure GmbH
  • 10.9.1 Overview
  • 10.9.2 Financial Performance
  • 10.9.3 Product Outlook
  • 10.9.4 Key Developments

11 Appendix

• 11.1 Related Research